Navigation Links
PINC trial launched to test new treatment for pre-invasive breast cancer
Date:3/2/2010

FAIRFAX, Va.Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

In January, the IBCI and CAPMM launched the PINC Trial, short for Preventing Invasive Breast Neoplasia with Chloroquine. This three-year clinical trial will test the effectiveness of the anti-malarial drug chloroquine in treating 90 women with ductal carcinoma in situ (DCIS), a type of breast cancer in which the cancer cells start in the milk ducts but have not yet become invasive and spread in the breast. Once the cancer cells start to spread in the breast and throughout the body, the condition is considered invasive and can often be fatal.

With an estimated 254,650 patients diagnosed in 2009 alone, breast cancer is the most common form of cancer in women according to statistics by the American Cancer Society. Approximately one quarter of those patients will have DCIS. Many more women are being diagnosed with DCIS, non-invasive breast cancer, with the routine use of screening mammography.

According to Kirsten Edmiston, MD, the trial's principal investigator and medical director of cancer services at Inova Health System, the trial is designed to prevent breast cancer cells from becoming deadly by killing pre-invasive cancer cells using a novel therapy with chloroquine, which has been used to treat malaria in the past.

"We have identified a particular cellular process called autophagy that is very involved in the survival of DCIS. In pre-clinical work, our team found that if we block autophagy in DCIS cells with chloroquine, that it kills the cells so that they're not able to become invasive," says Edmiston. "What this trial is proposing is to treat DCIS patients with chloroquine, an autophagy blocker before they receive
'/>"/>

Contact: Marjorie Musick
mmusick@gmu.edu
703-993-8781
George Mason University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Heart Pump Shows Promise in Trial
2. Trial to Test Gene Therapy for Angina in Women
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. MDS Pharma Services Wins Award for Management of Global Malaria Trial
7. New Ovarian Cancer Drug Trial Under Way
8. Study Questions Dead-End Cancer Clinical Trials
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
11. Clinical trials present better alternatives for dialysis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- Overeating is common during ... eat in moderation, an expert says. "Don,t arrive at ... calories if you know you,ll be attending a party, but ... Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount Kisco, ... to eat healthy during the day and even to have ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the ... the business has introduced its new collection of 2015 ... , The new prom outfits are guaranteed to contain ... They are specially designed for 2015. Anyone who wants ... visit its website before Jan. 26, 2015, the deadline ...
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... disorders may be linked to other medical problems including ... and psychiatric problems. ,Researchers conducted a study and ... had ADD. Results also show a high degree of ... of these patients also suffered severe memory impairment, depression, ...
... that giving adolescent girls estrogen treatments to keep them from ... on in life . Estrogen is thought to limit height ... women who had been assessed for estrogen therapy as girls ... had actually been treated with estrogen, and the other half ...
... 60 are affected by Parkinson’s disease. The condition is characterized ... from loss of facial rigidity // and a shuffling walk. ... of Parkinson’s disease may also be able to stop its ... found to completely halt the neurotoxic effects of a chemical ...
... study finds growth patterns in childhood can help predict which ... link a high birth weight, reaching peak growth at an ... having a low body mass index (BMI) at age 14, ... likelihood of the disease. ,For the study researchers used ...
... researchers suggest that the risk factors for heart attacks may ... studied, about two-thirds had at least one risk factor for ... of risk factors known as metabolic syndrome. One in three ... has been identified as a risk for heart disease and ...
... the number one cause of cancer death worldwide, accounting for ... disease is hard to detect in early and treatable stages, ... Studies have shown CT scans can identify the disease in ... lung cancer, but they also identify many noncancerous lesions in ...
Cached Medicine News:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... 2, 2011 Omnicell, Inc. (NASDAQ: OMCL ), a ... today announced results for its first quarter ended March 31, 2011. ... quarter of 2011 was $57.2 million as compared with $57.3 ... million or 5.5% from the first quarter 2010 revenue of ...
... (Hologic or the Company) (Nasdaq: HOLX ), a ... imaging systems and surgical products dedicated to serving the healthcare ... fiscal quarter ended March 26, 2011. ... $438.7 million. Net income was $82.4 million, or $0.31 ...
Cached Medicine Technology:Omnicell Announces First Quarter 2011 Results 2Omnicell Announces First Quarter 2011 Results 3Omnicell Announces First Quarter 2011 Results 4Omnicell Announces First Quarter 2011 Results 5Omnicell Announces First Quarter 2011 Results 6Omnicell Announces First Quarter 2011 Results 7Omnicell Announces First Quarter 2011 Results 8Omnicell Announces First Quarter 2011 Results 9Omnicell Announces First Quarter 2011 Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 2Hologic Announces Second Quarter Fiscal 2011 Operating Results 3Hologic Announces Second Quarter Fiscal 2011 Operating Results 4Hologic Announces Second Quarter Fiscal 2011 Operating Results 5Hologic Announces Second Quarter Fiscal 2011 Operating Results 6Hologic Announces Second Quarter Fiscal 2011 Operating Results 7Hologic Announces Second Quarter Fiscal 2011 Operating Results 8Hologic Announces Second Quarter Fiscal 2011 Operating Results 9Hologic Announces Second Quarter Fiscal 2011 Operating Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 11Hologic Announces Second Quarter Fiscal 2011 Operating Results 12Hologic Announces Second Quarter Fiscal 2011 Operating Results 13Hologic Announces Second Quarter Fiscal 2011 Operating Results 14Hologic Announces Second Quarter Fiscal 2011 Operating Results 15Hologic Announces Second Quarter Fiscal 2011 Operating Results 16Hologic Announces Second Quarter Fiscal 2011 Operating Results 17Hologic Announces Second Quarter Fiscal 2011 Operating Results 18
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight....
3 mm forked angled blades. Blade spread 7 mm. Flat serrated handle with polished finish. Overall length: 4.8 inches....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
Medicine Products: